Below is a list of clinical trials currently available through the Comprehensive Epilepsy Center at Montefiore Medical Center:
For people who have clusters of seizures: A study to evaluate the safety and effectiveness of intranasal midazolam in patients with seizure clusters. More Information Inclusion Criteria for Clinical and Medication Trials
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intranasal Midazolam (USL261) in the Outpatient Treatment of Subjects with Seizure Clusters ARTEMIS-I: Acute Rescue Therapy in Epilepsy with Midazolam Intranasal Spray-I
- Seizure clusters that last at least >10 minutes which are evident within 6 hours.
- Four or more seizure clusters per year
- Body weight of 50kg or more.
For people with epilepsy who take carbamazepine: A study to assess the safety and tolerability of intravenous carbamazepine in adults with epilepsy. More Information Inclusion Criteria for Clinical and Medication Trials
Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients with Epilepsy
- Patients 18 years of age and older
- Currently taking 1200-2000mg of carbamazepine per day
- Interested in a one week inpatient IV carbamazepine study
For people with epilepsy who take one to two epilepsy medications and still experience seizures: A historical control study to assess the safety and efficacy of eslicarbazepine acetate as monotherapy. More Information Inclusion Criteria for Clinical and Medication Trials
Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects with Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs
- Aged 16 – 70 years
- Average 2 or more focal onset seizures per month
- Taking 1 or 2 antiepileptic medications
For patients who take one to four epilepsy medications and still experience seizures: A dose-range add-on study to evaluate the efficacy and safety of an interleukin beta enzyme inhibitor in subjects with treatment-resistant partial epilepsy. More Information Inclusion Criteria for Clinical and Medication Trials
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of VX 765 in Subjects with Treatment-Resistant Partial Epilepsy/VRX11-765-402
- Aged 18 years or older
- Currently taking 1 or more antiepileptic medications
- Having three or more seizures per month
For patients interested in a stress management behavioral intervention to reduce seizures: An add-on randomized controlled trial using electronic diaries for stress management in epilepsy. More Information
For inpatients at the Comprehensive Epilepsy Center: A feasibility study evaluating a breath-actuated pressurized metered dose Inhaler. More Information Inclusion Criteria for Clinical and Medication Trials
Stress Management Intervention for Living with Epilepsy (SMILE) Study:
Subjects experiencing 2 or more seizures per month can be referred for consideration.
For more information about these trials please contact our research team at 718-920-2898.